Centene Corporation
CNC Healthcare Healthcare Plans
Centene Corporation’s revenue for fiscal 2025 (year ended December 2025) was $194.8 billion, up 19.4% from fiscal 2024.
- Revenue
- +1.93%
- EPS
- +99.0%
- Free cash flow
- −437.4%
- Total debt
- −11.6%
Quarter to September 2026, against a year earlier
Follow CNC
Alert me
Centene Corporation (CNC) valuation and DCF model
At $69.74 the price implies free cash flow after share-based pay growing −8.3% a year for ten years.
Free cash flow after share-based pay grew 7.2% a year over the last ten years, −17.7% over the last five. The price asks for 15.5 points a year less than its ten-year rate. The industry’s median company is priced for −2.1%.
In December 2017 the price assumed −6.3% a year; Centene Corporation went on to grow free cash flow after share-based pay 20.4% a year to FY2025.
- The price needs
- −8.3% a year for ten years
- $69.74
- today’s price
- Its base case
- 7.2% a year for five years, then 4.3%
- $168.89
- 142.2% above today’s price
Base case on its own ten-year record Centene Corporation’s own growth, carried forward
Its assumptions
Powerpack lets you start from a scenario and type over any of them.
How we got there$32.55b 10 years of cash to equity+$43.03b terminal value+$8.04b net cash=$83.62b equity value÷495.12m shares=$168.89 per share
Valuation against its own history
| Multiple | Current | 5Y avg | 10Y avg | vs 10Y avg | Industry median | vs industry | 10Y range |
|---|---|---|---|---|---|---|---|
| P/E | 23.48× | 24.55× | 22.54× | 4% above | 22.50× | 4% above | |
| P/FCF | 8.73× | 8.50× | 14.73× | 41% below | 14.76× | 41% below | |
| P/B | 1.55× | 1.45× | 1.70× | 9% below | 2.77× | 44% below | |
| EV/EBITDA | 11.81× | 12.72× | 11.29× | 5% above | 12.61× | 6% below | |
| EV/Sales | 0.13× | 0.21× | 0.29× | 55% below | 0.36× | 64% below |
CNC trades at 23.48× P/E, against a 10-year average of 22.54× (range 9.66×–38.34×). That is dearer than 67% of the last 9 year-end readings; re-rating to the average implies $66.96 per share.